The high prevalence and significant burden of osteoarthritis (OA) are well known. But it’s becoming apparent that OA research efforts don’t necessarily match disease prevalence or disability. The International Foot and Ankle Osteoarthritis Consortium (IFOAC) is an international organization of volunteers that seeks to highlight a major and often overlooked problem in OA research—foot and…
Search results for: osteoporosis
From Contraception to Breastfeeding: Experts Address Reproductive Health & Medication Management
ACR CONVERGENCE 2021—Rheumatologists are often left in a challenging space when managing medications for patients with rheumatic diseases in relation to contraception, pregnancy and breastfeeding, especially with many novel immunosuppressants and often a dearth of pregnancy safety data. On Nov. 6 during ACR Convergence 2021, leading reproductive health experts came together to speak on this…
Meet New ACR President Kenneth G. Saag, MD, MSc
Kenneth G. Saag, MD, MSc, is a nationally recognized expert & researcher in the epidemiology of gout, osteoporosis & rheumatoid arthritis. Dr. Saag brings a penchant for problem solving & a strong belief in the power of collaboration to his newest role in the College as the 85th ACR president.
Tips for Transitioning Patients from Pediatric to Adult Rheumatology Care
Approximately 50% of young adult patients with childhood-onset rheumatic diseases become lost to follow-up within the first year of transferring to adult rheumatology care, mirroring the statistics of other subspecialties.1,2 One of the challenges cited most consistently by young adult patients and their families relates to differences between rheumatology care delivery in the pediatric and…
Case Report: Drug-Induced Lupus
The incidence of drug-induced lupus continues to rise as clinicians expand their therapeutic armamentarium. An estimated 15,000–30,000 cases of drug-induced lupus occur every year in the U.S. alone.1 It is a well-known, but rare, complication of commonly used medications, such as anti-hypertensive, anti-arrhythmic and anti-epileptic drugs, as well as biologic and immune checkpoint therapies.2,3 The…
Food & Disease: How Diet May Affect Rheumatic & Musculoskeletal Diseases
Patients’ questions about pro- and anti-inflammatory diets can be challenging to address. Dr. Elena Nikiphorou provided insight into the latest research regarding the role of diet in rheumatic and musculoskeletal diseases.
How to Prepare for the ABIM Rheumatology Certification Exam
Preparing for the American Board of Internal Medicine (ABIM) Rheumatology Certification Exam can easily be one of the most anxiety-inducing times for young trainees (and even seasoned rheumatologists). Once again, you are asked to demonstrate mastery of your knowledge in a medical field, and this time it is for the field of rheumatology—a discipline with…
Bipartisan DXA Bill Under Consideration in Congress
The Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act would set a $98 floor for Medicare reimbursement for the dual-energy X-ray absorptiometry (DXA) bone density test.
The Race Is On: Clinical Trials Begin for Agents Biosimilar to Denosumab
As the U.S. and other patents for branded denosumab products get closer to expiring, drug manufacturers are initiating clinical trials for more affordable, biosimilar versions of the treatment.
Study: Can Avacopan Replace Steroids in ANCA-Associated Vasculitis?
A phase 3 trial described in The New England Journal of Medicine (NEJM) highlights the potential of a C5a receptor inhibitor, avacopan, for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis.1 Avacopan may potentially offer a steroid-sparing option for the treatment of this serious disease. Current Treatment of ANCA-Associated Vasculitis Morbidity and mortality from ANCA-associated vasculitis have…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 57
- Next Page »